A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection.

We have completed a phase 1 safety and immunogenicity trial with hepatitis C virus (HCV) envelope glycoproteins, E1 and E2, with MF59 adjuvant as a candidate vaccine. Neutralizing activity to HCV genotype 1a was detected in approximately 25% of the vaccinee sera. In this study, we evaluated vaccinee...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Keith Meyer, Arup Banerjee, Sharon E Frey, Robert B Belshe, Ranjit Ray
Format:	Artigo
Sprog:	Inglês
Udgivet:	Public Library of Science (PLoS) 2011-01-01
Serier:	PLoS ONE
Online adgang:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0023699&type=printable
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!